Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

November 6, 2025 7:00 AM EST

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA 2,3 receptor positive allosteric modulator

Deepens Axsomes broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into an agreement to obtain exclusive global rights to AZD7325, a novel oral GABAA receptor 2,3 subtype-selective... More